Tag Archives: proxy

BMS-Celgene merger chances improve with backing from proxy advisers

When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. Institutional Shareholder Services and Glass Lewis both said Friday that they’re backing the transaction. ISS pointed to deal’s “sound” strategic rationale and cost-cutting potential, while Glass Lewis said the buy “presents the opportunity for potentially… Read More »

Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed. In a Friday proxy filing, the company said it had drafted former Celgene CEO and M&A engineer Bob Hugin to head up a new deal-focused committee. Three current board members will round out the panel,… Read More »